Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 8/2018

01-08-2018 | HIV/AIDs (C Yoon, Section Editor)

Benefits and Risks of Statin Therapy in the HIV-Infected Population

Authors: Mosepele Mosepele, Onkabetse J. Molefe-Baikai, Steven K. Grinspoon, Virginia A. Triant

Published in: Current Infectious Disease Reports | Issue 8/2018

Login to get access

Abstract

Purpose of Review

HIV-infected patients face an increased risk for cardiovascular disease (CVD), estimated at 1.5- to 2-fold as compared to HIV-uninfected persons. This review provides a recent (within preceding 5 years) summary of the role of statin therapy and associated role in CVD risk reduction among HIV-infected patients on anti-retroviral therapy.

Recent Findings

Statins remain the preferred agents for reducing risk for CVD among HIV-infected populations based on guidance extrapolated from general population (HIV-uninfected) cholesterol treatment guidelines across different settings globally. However, HIV-infected patients are consistently under prescribed statin therapy when compared to their HIV-uninfected counterparts. The most commonly studied statins in clinical care and small randomized and cohort studies have been rosuvastatin and atorvastatin. Both agents are preferred for their potent lipid-lowering effects and their favorable or neutral pleotropic effects on chronic inflammation, renal function, and hepatic steatosis among others. However, growing experience with the newer glucuronidated pitavastatin suggests that this agent has virtually no adverse drug interactions with ART or effects on glucose metabolism—all marked additional benefits when compared with rosuvastatin and atorvastatin while maintaining comparable anti-lipid effects. Pitavastatin is therefore the statin of choice for the ongoing largest trial (6500 participants) to test the benefits of statin therapy among HIV-infected adults.

Summary

Statins are underutilized in the prevention of CVD in HIV-infected populations based on criteria in established cholesterol guidelines. There is a potential role for statin therapy for HIV-infected patients who do not meet guideline criteria which will be further delineated through ongoing clinical trials.
Literature
1.
Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569–82.PubMed
2.
3.
4.
Schonewille M, Freark de Boer J, Mele L, Wolters H, Bloks VW, Wolters JC, et al. Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. J Lipid Res. 2016;57(8):1455–64.CrossRefPubMedPubMedCentral
5.
•• Gili S, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016;37(48):3600–9. This is a recent meta-analysis of all research on statin use in HIV-positive patients on combination anti-retroviral therapy (cART). This meta-analysis not only demonstares efficacy of statins in HIV-infected patients receiving ART but also demontrates a good safety profile CrossRefPubMed
6.
• Banach M, et al. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacol Res. 2016;111:343–56. A recent meta-analysis of all randomized controlled trials on the effect of statins on plasma lipid in HIV-infected patients. The main findings were significant reductions in plasma cholesterols (LDL-C, total C, and non-HDL-C) and elevations in plasma HDL-C CrossRefPubMed
7.
Stein JH. Management of lipid levels and cardiovascular disease in HIV-infected individuals: just give them a statin? Top Antivir Med. 2016;23(5):169–73.PubMed
8.
Wongprikorn A, Sukasem C, Puangpetch A, Numthavej P, Thakkinstian A, Kiertiburanakul S. Effects of pitavastatin on lipid profiles in HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir: a randomized, double-blind, crossover study. PLoS One. 2016;11(6):e0157531.CrossRefPubMedPubMedCentral
9.
Longenecker CT, Sattar A, Gilkeson R, McComsey GA. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30(14):2195–203.CrossRefPubMed
10.
• Nixon DE, et al. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). J Clin Lipidol. 2017;11(1):61–9. This multicenter, prospective, randomised, double-blind, placebo-controlled, pilot study examined the effect of atorvastatin in a wide array of cellular, soluble, and lipoprotein biomarkers of inflammation among virally suppressed HIV-infected patients. The study demontrated a significant reduction in LDL cholesterol, oxidized LDL, and lipoprotein-associated phospholipase A2. A reduction in these biomarkers suggests a possible reduction in CVD by statins in virally suppressed HIV-infected patients CrossRefPubMed
11.
Stone NJ, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934.CrossRefPubMed
12.
Limsreng S, Marcy O, Ly S, Ouk V, Chanroeurn H, Thavary S, et al. Dyslipidemias and elevated cardiovascular risk on lopinavir-based antiretroviral therapy in Cambodia. PLoS One. 2016;11(8):e0160306.CrossRefPubMedPubMedCentral
13.
Lee FJ, Monteiro P, Baker D, Bloch M, Roth N, Finlayson R, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. HIV Med. 2016;17(8):605–14.CrossRefPubMed
14.
Wangpatharawanit P, Sungkanuparph S. Switching lopinavir/ritonavir to atazanavir/ritonavir vs adding atorvastatin in HIV-infected patients receiving second-line antiretroviral therapy with hypercholesterolemia: a randomized controlled trial. Clin Infect Dis. 2016;63(6):818–20.CrossRefPubMed
15.
Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 2015;14:57.CrossRefPubMedPubMedCentral
16.
Hileman CO, Turner R, Funderburg NT, Semba RD, McComsey G. Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS. 2016;30(1):65–73.PubMed
17.
Aberg JA, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4(7):e284–94.CrossRefPubMed
18.
Joshi PH, Miller PE, Martin SS, Jones SR, Massaro JM, D’Agostino RB Sr, et al. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. AIDS. 2017;31(7):965–71.CrossRefPubMed
19.
Nou E, Lu MT, Looby SE, Fitch KV, Kim EA, Lee H, et al. Serum oxidized low-density lipoprotein decreases in response to statin therapy and relates independently to reductions in coronary plaque in patients with HIV. AIDS. 2016;30(4):583–90.CrossRefPubMed
20.
Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, et al. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-alpha in HIV-infected patients treated with ritonavir-boosted protease inhibitors. HIV Clin Trials. 2012;13(3):153–61.CrossRefPubMed
21.
Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, et al. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52(3):387–95.CrossRefPubMedPubMedCentral
22.
Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015;(3):Cd008226.
23.
Hileman CO, Tangpricha V, Sattar A, McComsey GA. Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. J Acquir Immune Defic Syndr. 2017;74(5):539–47.CrossRefPubMedPubMedCentral
24.
Hileman CO, McComsey GA. The effect of rosuvastatin on vascular disease differs by smoking status in treated HIV infection. AIDS Res Hum Retrovir. 2017;
25.
Phan BAP, Weigel B, Ma Y, Scherzer R, Li D, Hur S, et al. Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-infected adults with carotid atherosclerosis. Circ Cardiovasc Imaging. 2017;10(7):e005995.CrossRefPubMedPubMedCentral
26.
Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28(14):2061–70.CrossRefPubMed
27.
Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial infarction, stroke, and mortality in cART-treated HIV patients on statins. AIDS Patient Care STDs. 2015;29(6):307–13.CrossRefPubMedPubMedCentral
28.
Lang S, Lacombe JM, Mary-Krause M, Partisani M, Bidegain F, Cotte L, et al. Is impact of statin therapy on all-cause mortality different in HIV-infected individuals compared to general population? Results from the FHDH-ANRS CO4 Cohort. PLoS One. 2015;10(7):e0133358.CrossRefPubMedPubMedCentral
29.
Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One. 2011;6(7):e21843.CrossRefPubMedPubMedCentral
30.
Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS One. 2013;8(3):e52828.CrossRefPubMedPubMedCentral
31.
Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013;56(10):1471–9.CrossRefPubMedPubMedCentral
32.
Bernal E, Marín I, Masiá M, Gutiérrez F. Statins in HIV-infected patients: potential beneficial effects and clinical use. AIDS Rev. 2017;19(2):59–71.PubMed
33.
Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J Am Coll Cardiol. 2014;63(23):2491–502.CrossRefPubMed
34.
Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS. 2016;30(2):171–83.CrossRefPubMed
35.
Aslangul E, Fellahi S, Assoumou LK, Bastard JP, Capeau J, Costagliola D. High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. AIDS. 2011;25(8):1128–31.CrossRefPubMed
36.
Fichtenbaum CJ, Evans SE, Aberg JA. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS. 2011;25(16):2053.CrossRefPubMed
37.
Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017;31(6):797–806.CrossRefPubMed
38.
Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(4):396–404.CrossRefPubMedPubMedCentral
39.
Yadav A, Betts MR, Collman RG. Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders. J Neuro-Oncol. 2016;22(5):584–96.
40.
Dirajlal-Fargo S, Kinley B, Jiang Y, Longenecker CT, Hileman CO, Debanne S, et al. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS. 2015;29(3):313–21.CrossRefPubMed
41.
Eckard AR, Cho S, O’Riordan MA, McComsey GA. Kallistatin levels in HIV-infected patients and effects of statin therapy. Biomarkers. 2017;22(1):55–62.CrossRefPubMed
42.
Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52–63.CrossRefPubMedPubMedCentral
43.
• Weijma RG, et al. The effect of rosuvastatin on markers of immune activation in treatment-naive human immunodeficiency virus-patients. Open Forum Infect Dis. 2016;3(1):ofv201. This randomized double-blind placebo-controlled crossover study assessed the effects of rosuvastatin in treatment-naive male HIV-infected patients on markers of immune activation. The effect of rosuvastatin on markers of immune activation was found to be minimal CrossRefPubMed
44.
• Zanni MV, et al. Effects of antiretroviral therapy on immune function and arterial inflammation in treatment-naive patients with human immunodeficiency virus infection. JAMA Cardiol. 2016;1(4):474–80. This mechanistic study highlights the strong and persistent arterial inflammation induced by HIV infection despite initiation of ART CrossRefPubMedPubMedCentral
45.
Allen SC, Mamotte CDS. Pleiotropic and adverse effects of statins—do epigenetics play a role? J Pharmacol Exp Ther. 2017;362(2):319–26.CrossRefPubMed
46.
El-Far M, Tremblay CL. Gut microbial diversity in HIV infection post combined antiretroviral therapy: a key target for prevention of cardiovascular disease. Curr Opin HIV AIDS. 2018;13(1):38–44.CrossRefPubMed
47.
Bandera A, de Benedetto I, Bozzi G, Gori A. Altered gut microbiome composition in HIV infection: causes, effects and potential intervention. Curr Opin HIV AIDS. 2018;13(1):73–80.CrossRefPubMed
48.
Funderburg NT, et al. Rosuvastatin decreases intestinal fatty acid binding protein (I-FABP), but does not alter zonulin or lipopolysaccharide binding protein (LBP) levels, in HIV-infected subjects on antiretroviral therapy. Pathog Immun. 2016;1(1):118–28.CrossRefPubMedPubMedCentral
49.
50.
Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, et al. Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS. 2016;30(18):2805–13.CrossRefPubMed
51.
Erlandson KM, Fiorillo S, Masawi F, Scherzinger A, McComsey GA, Lake JE, et al. Antiretroviral initiation is associated with increased skeletal muscle area and fat content. AIDS. 2017;31(13):1831–8.CrossRefPubMed
52.
Oliveira VH, Wiechmann SL, Narciso AMS, Webel AR, Deminice R. Muscle strength is impaired in men but not in women living with HIV taking antiretroviral therapy. Antivir Ther. 2017;23:11–9.CrossRef
53.
Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Effects of 96 weeks of rosuvastatin on bone, muscle, and fat in HIV-infected adults on effective antiretroviral therapy. AIDS Res Hum Retrovir. 2016;32(4):311–6.CrossRefPubMedPubMedCentral
54.
Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883–9.CrossRefPubMed
55.
Moyle G, Carr A. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities. HIV Clin Trials. 2002;3(1):89–98.PubMed
56.
Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377(9772):1198–209.CrossRefPubMed
57.
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96.
58.
Lo J, Lu MT, Kim EA, Nou E, Hallett TR, Park J, et al. Statin effects to reduce hepatosteatosis as measured by computed tomography in patients with human immunodeficiency virus. Open Forum Infect Dis. 2016;3(2):ofw062.CrossRefPubMedPubMedCentral
59.
Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106(1):71–7.CrossRefPubMed
60.
Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148–56.CrossRefPubMedPubMedCentral
61.
Williams DW, et al. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res. 2014;12(2):85–96.CrossRefPubMedPubMedCentral
62.
Todd JV, Cole SR, Wohl DA, Simpson RJ Jr, Jonsson Funk M, Brookhart MA, et al. Underutilization of statins when indicated in HIV-seropositive and seronegative women. AIDS Patient Care STDs. 2017;31(11):447–54.CrossRefPubMedPubMedCentral
63.
Mosepele M, Letsatsi V, Mokgatlhe L, Hudson FP, Gross R. Cholesterol screening and statin prescription is low among HIV-infected patients on protease-inhibitor regimens in Botswana. Open AIDS J. 2017;11:45–51.CrossRefPubMedPubMedCentral
64.
Guo F, Hsieh E, Lv W, Han Y, Xie J, Li Y, et al. Cardiovascular disease risk among Chinese antiretroviral-naive adults with advanced HIV disease. BMC Infect Dis. 2017;17(1):287.CrossRefPubMedPubMedCentral
65.
Clement ME, Park LP, Navar AM, Okeke NL, Pencina MJ, Douglas PS, et al. Statin utilization and recommendations among HIV- and HCV-infected veterans: a cohort study. Clin Infect Dis. 2016;63(3):407–13.CrossRefPubMedPubMedCentral
66.
van Zoest RA, et al. Suboptimal primary and secondary cardiovascular disease prevention in HIV-positive individuals on antiretroviral therapy. Eur J Prev Cardiol. 2017;24(12):1297–307.CrossRefPubMedPubMedCentral
67.
De Socio GV, et al. Statins and aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. Infection. 2016;44(5):589–97.CrossRefPubMed
68.
Ladapo JA, Richards AK, DeWitt CM, Harawa NT, Shoptaw S, Cunningham WE, et al. Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study. J Am Heart Assoc. 2017;6(11):e007107.CrossRefPubMedPubMedCentral
69.
Maggi P, de Socio GV, Cicalini S, D’Abbraccio M, Dettorre G, di Biagio A, et al. Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. New Microbiol. 2017;40(2):139–42.PubMed
70.
Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, et al. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: results from the PACS-HIV lipids substudy. Am Heart J. 2017;183:91–101.CrossRefPubMed
71.
Monroe AK, Fu W, Zikusoka MN, Jacobson LP, Witt MD, Palella FJ, et al. Low-density lipoprotein cholesterol levels and statin treatment by HIV status among multicenter AIDS cohort study men. AIDS Res Hum Retrovir. 2015;31(6):593–602.CrossRefPubMedPubMedCentral
72.
Drechsler H, Ayers C, Cutrell J, Maalouf N, Tebas P, Bedimo R. Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One. 2017;12(3):e0172175.CrossRefPubMedPubMedCentral
73.
Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol. 2015;115(12):1760–6.CrossRefPubMed
74.
Wiggins BS, Lamprecht DG, Page RL, Saseen JJ. Recommendations for managing drug-drug interactions with statins and HIV medications. Am J Cardiovasc Drugs. 2017;17(5):375–89.CrossRefPubMed
75.
Blonk M, van Beek M, Colbers A, Schouwenberg B, Burger D. Pharmacokinetic drug-drug interaction study between raltegravir and atorvastatin 20 mg in healthy volunteers. J Acquir Immune Defic Syndr. 2015;69(1):44–51.CrossRefPubMed
76.
Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52(10):815–31.CrossRefPubMed
77.
Custodio JM, Wang H, Hao J, Lepist EI, Ray AS, Andrews J, et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol. 2014;54(6):649–56.CrossRefPubMed
78.
Suttels V, Florence E, Leys J, Vekemans M, van den Ende J, Vlieghe E, et al. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. J Med Case Rep. 2015;9:190.CrossRefPubMedPubMedCentral
79.
Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT, et al. Statin use is associated with incident diabetes mellitus among patients in the HIV outpatient study. J Acquir Immune Defic Syndr. 2015;69(3):306–11.CrossRefPubMedPubMedCentral
80.
Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. Clin Infect Dis. 2015;61(10):1566–72.CrossRefPubMedPubMedCentral
81.
Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, et al. Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infect Dis. 2017;17(1):43.CrossRefPubMedPubMedCentral
82.
Calza L, Colangeli V, Magistrelli E, Manfredi R, Bon I, Re MC, et al. No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy. HIV Med. 2016;17(8):631–3.CrossRefPubMed
83.
Ou HT, Chang KC, Li CY, Yang CY, Ko NY. Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: a nation-wide longitudinal cohort study 2000-2011. Int J Cardiol. 2017;230:592–8.CrossRefPubMed
84.
Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, et al. Risk of acute liver injury after statin initiation by human immunodeficiency virus and chronic hepatitis C virus infection status. Clin Infect Dis. 2017;65(9):1542–50.CrossRefPubMedPubMedCentral
85.
Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP Jr, Klein D, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150(5):301–13.CrossRefPubMed
86.
• Calza L, et al. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. Aids. 2017;31(5):681–8. This study reports a strong association between risk of statin-induced myalgia and vitamin D deficiency among HIV-infected adults CrossRefPubMed
87.
Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27(8):1803–10.CrossRefPubMed
88.
Melvin AJ, Montepiedra G, Aaron L, Meyer WA 3rd, Spiegel HM, Borkowsky W, et al. Safety and efficacy of atorvastatin in human immunodeficiency virus-infected children, adolescents and young adults with hyperlipidemia. Pediatr Infect Dis J. 2017;36(1):53–60.CrossRefPubMedPubMedCentral
89.
Kakafika A, Liamis G, Elisaf M, Mikhailidis D. Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin. 2001;17(3):230–1.CrossRefPubMed
90.
Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Top Antivir Med. 2015;23(4):146–9.PubMed
91.
Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr. 2014;67(4):390–6.CrossRefPubMedPubMedCentral
Metadata
Title
Benefits and Risks of Statin Therapy in the HIV-Infected Population
Authors
Mosepele Mosepele
Onkabetse J. Molefe-Baikai
Steven K. Grinspoon
Virginia A. Triant
Publication date
01-08-2018
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 8/2018
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-018-0628-7

Other articles of this Issue 8/2018

Current Infectious Disease Reports 8/2018 Go to the issue

Respiratory Infections (F Arnold, Section Editor)

Comparative Study of Molecular Approaches for the Detection of Influenza Virus from Patient Samples Using Real-time PCR: Prospective Disease Burden Study in Kerala (India) from 2010 to 2016

Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile

Tropical, Travel, and Emerging Infections (L Chen and A Boggild, Section Editors)

Improving Dengue Diagnostics and Management Through Innovative Technology

Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Antimicrobial Resistance to Agents Used for Staphylococcus aureus Decolonization: Is There a Reason for Concern?

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)

Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation

Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits